BC Cancer Agency scientists discover new gene that suppresses tumour growth

Researchers discovered a novel gene, HACE1, which suppresses the growth of human tumours in multiple cancers including breast, lung and liver cancers as well as melanomas, lymphomas and sarcomas. The discovery of this gene clearly impacts a wide range of cancers, and provides a novel link between cellular stress and cancer with a potential to improve treatments for many cancer patients.

BC Cancer Agency study tests value of online emotional support

The Agency launched the first-of-its-kind study in Canada to test the value of online emotional support in improving the quality of life of young women with breast cancer. The study will investigate whether the online skills and support group can reduce distress, change perception of how much breast cancer interferes with the physical well-being, and increase participants’ confidence in coping...

Gene mutation lets leukemia fight drug that helps remission

Researchers at the BC Cancer Agency’s Terry Fox Laboratory discovered that chronic myeloid leukemia (CML) stem cells spontaneously develop resistance to Gleevec, possibly due to continuing genetic mutations. Gleevec is an oral chemotherapy drug that helps reduce the symptoms of CML and allows patients to return to a normal life.

Breakthrough study halts growth of prostate cancer in the lab

An Agency study engineered a molecule that blocked the growth of prostate cancer and shrank the size of the tumour. This sets the stage for the development of innovative approaches to treat androgen-independent prostate cancer — the advanced stage of the disease for which there is no cure.

$95 Million cancer research centre opens

The Agency’s new $95 million, Research Centre, funded partly by BC Cancer Foundation donors, opened in Vancouver. It received Canada’s first LEED Gold designation for a medical facility and has become a symbol and icon for its groundbreaking translational research output.

Protein may help understand link between infection and cancer

Researchers published findings in the journal Immunity about the activity of a protein, SHIP, which regulates how we respond to microbial infections and inflammation-inducing agents. This research has implications for cancer control and increases our understanding of allergies and autoimmune disorders such as asthma. It could play an important role in controlling septic shock in hospital patients.